The Interplay of Pathology, Prevention and Treatment in Cardio-Metabolic Diseases
Abstract
This chapter explores the intricate relationship between heart disorders and metabolism disorders, sometimes known as cardio-metabolic diseases. These illnesses, hypertension, diabetes, metabolic syndrome, and coronary artery disease, have similar underlying pathophysiological mechanisms and risk factors. This chapter explores the epidemiology of cardio-metabolic disorders, emphasising the significant global health burden associated with these conditions as well as their rising prevalence. Insulin resistance, dyslipidemia, endothelial dysfunction, and chronic inflammation are some critical pathophysiological pathways highlighted. Cardio-metabolic diseases are linked and proceed through these processes. The genesis and management of various disorders are also examined in this chapter in light of genetic, environmental, and lifestyle variables. The risk of cardio-metabolic disorders is decreased, and preventive interventions, such as dietary and physical activity changes and weight management, manage their progression. The chapter also analyses new medicines and current pharmaceutical treatments to enhance therapeutic results and target the underlying mechanisms. New insights into potential future routes for prevention and therapy are provided by emerging research on the role of the gut microbiome, innovative biomarkers, and personalised medicine techniques. In order to enhance patient outcomes and lessen the associated healthcare burden, the chapter’s conclusion emphasises…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.